PMID- 37372460
OWN - NLM
STAT- MEDLINE
DCOM- 20230629
LR  - 20230701
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 14
IP  - 6
DP  - 2023 Jun 16
TI  - A Comprehensive Pan-Cancer Analysis of the Potential Biological Functions and 
      Prognosis Values of RICTOR.
LID - 10.3390/genes14061280 [doi]
LID - 1280
AB  - The importance of the network defined by phosphatidylinositol-3-kinase (PI3K), 
      AKT and mammalian target of rapamycin (mTOR) downstream of Receptor Tyrosine 
      Kinase (RTK) has been recognized for many years. However, the central role of 
      RICTOR (rapamycin-insensitive companion of mTOR) in this pathway has only 
      recently come to light. The function of RICTOR in pan-cancer still needs to be 
      systematically elucidated. In this study, we examined RICTOR's molecular 
      characteristics and clinical prognostic value by pan-cancer analysis. Our 
      findings indicate that RICTOR was overexpressed in twelve cancer types, and a 
      high RICTOR expression was linked to poor overall survival. Moreover, the CRISPR 
      Achilles' knockout analysis revealed that RICTOR was a critical gene for the 
      survival of many tumor cells. Function analysis revealed that RICTOR-related 
      genes were mainly involved in TOR signaling and cell growth. We further 
      demonstrated that the RICTOR expression was significantly influenced by genetic 
      alteration and DNA-methylation in multiple cancer types. Additionally, we found a 
      positive relationship between RICTOR expression and the immune infiltration of 
      macrophages and cancer-associated fibroblasts in Colon adenocarcinoma and Head 
      and Neck squamous cell carcinoma. Finally, we validated the ability of RICTOR in 
      sustaining tumor growth and invasion in the Hela cell line using cell-cycle 
      analysis, the cell proliferation assay, and wound-healing assay. Our pan-cancer 
      analysis highlights the critical role of RICTOR in tumor progression and its 
      potential as a prognostic marker for various cancer types.
FAU - Sun, Ying
AU  - Sun Y
AD  - Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, China.
AD  - MOE Key Laboratory of Gene Function and Regulation, Guangzhou Key Laboratory of 
      Healthy Aging Research and SYSU-BCM Joint Research Center, School of Life 
      Sciences, Sun Yat-sen University, Guangzhou 510275, China.
FAU - Li, Rui
AU  - Li R
AD  - MOE Key Laboratory of Gene Function and Regulation, Guangzhou Key Laboratory of 
      Healthy Aging Research and SYSU-BCM Joint Research Center, School of Life 
      Sciences, Sun Yat-sen University, Guangzhou 510275, China.
FAU - Nong, Baoting
AU  - Nong B
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou 510120, China.
FAU - Songyang, Zhou
AU  - Songyang Z
AD  - MOE Key Laboratory of Gene Function and Regulation, Guangzhou Key Laboratory of 
      Healthy Aging Research and SYSU-BCM Joint Research Center, School of Life 
      Sciences, Sun Yat-sen University, Guangzhou 510275, China.
FAU - Wang, Xianren
AU  - Wang X
AD  - Department of Otolarygology, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou 510080, China.
FAU - Ma, Wenbin
AU  - Ma W
AUID- ORCID: 0000-0001-8774-7593
AD  - MOE Key Laboratory of Gene Function and Regulation, Guangzhou Key Laboratory of 
      Healthy Aging Research and SYSU-BCM Joint Research Center, School of Life 
      Sciences, Sun Yat-sen University, Guangzhou 510275, China.
FAU - Zhou, Qin
AU  - Zhou Q
AUID- ORCID: 0000-0002-7205-082X
AD  - Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, China.
AD  - NHC Key Laboratory of Clinical Nephrology and Guangdong Provincial Key Laboratory 
      of Nephrology, Sun Yat-Sen University, Guangzhou 510080, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230616
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
RN  - 0 (Rapamycin-Insensitive Companion of mTOR Protein)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - 0 (Transcription Factors)
RN  - W36ZG6FT64 (Sirolimus)
RN  - 0 (RICTOR protein, human)
SB  - IM
MH  - Humans
MH  - HeLa Cells
MH  - *Adenocarcinoma
MH  - Rapamycin-Insensitive Companion of mTOR Protein/genetics/metabolism
MH  - *Colonic Neoplasms
MH  - TOR Serine-Threonine Kinases/genetics/metabolism
MH  - Transcription Factors/metabolism
MH  - Sirolimus
MH  - Prognosis
PMC - PMC10298440
OTO - NOTNLM
OT  - Pan-cancer
OT  - RICTOR
OT  - mTORC2
COIS- The authors declare no conflict of interest.
EDAT- 2023/06/28 06:42
MHDA- 2023/06/29 06:42
PMCR- 2023/06/16
CRDT- 2023/06/28 01:13
PHST- 2023/05/06 00:00 [received]
PHST- 2023/06/01 00:00 [revised]
PHST- 2023/06/14 00:00 [accepted]
PHST- 2023/06/29 06:42 [medline]
PHST- 2023/06/28 06:42 [pubmed]
PHST- 2023/06/28 01:13 [entrez]
PHST- 2023/06/16 00:00 [pmc-release]
AID - genes14061280 [pii]
AID - genes-14-01280 [pii]
AID - 10.3390/genes14061280 [doi]
PST - epublish
SO  - Genes (Basel). 2023 Jun 16;14(6):1280. doi: 10.3390/genes14061280.